Home » JUBILANT MAY UNVEIL A BID OF USD 500 MN FOR CAMBREX
JUBILANT MAY UNVEIL A BID OF USD 500 MN FOR CAMBREX
Jubilant Organosys seems to have identified the New Jersey based NYSE-listed life-sciences company, Cambrex, as one of its potential acquisition targets, as it looks for big buys in the US and Europe. The domestic integrated pharma player could unveil a bid with valuation more than USD 500 mn following a due diligence in the next 3-6 months.
Myiris
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
07May
-
14May
-
30May